May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol

  • Authors:
    • Massimo Serra
    • Michela Pasello
    • Maria Cristina Manara
    • Katia Scotlandi
    • Stefano Ferrari
    • Franco Bertoni
    • Mario Mercuri
    • Thor Andreas Alvegard
    • Piero Picci
    • Gaetano Bacci
    • Sigbjørn Smeland
  • View Affiliations

  • Published online on: Friday, December 1, 2006
  • Pages: 1459-1468
  • DOI: 10.3892/ijo.29.6.1459

Abstract

The aim was to evaluate the clinical impact of P-glycoprotein in primary non-metastatic high-grade osteosarcoma patients, treated with neoadjuvant chemotherapy protocols. P-glycoprotein was assessed by immunohistochemistry on paraffin-embedded tissue samples collected at time of diagnosis from 94 osteosarcoma patients, treated with the Italian Sarcoma Group/Scandinavian Sarcoma Group 1 (ISG/SSG 1) protocol. P-glycoprotein-positivity at diagnosis was found in 53/94 ISG/SSG 1 cases (56%) and emerged as the single factor significantly associated with an unfavourable outcome from survival and multivariate analyses. A comparative analysis of the subgroup of 94 patients considered for P-glycoprotein evaluation and the whole series of ISG/SSG 1 patients showed that this marker retained its prognostic value also in the latter group. In osteosarcoma patients treated with doxorubicin-based chemotherapy protocols, P-glycoprotein overexpression at diagnosis is an important adverse prognostic factor for outcome. P-glycoprotein evaluation can therefore constitute the basis for stratifying, at diagnosis, osteosarcoma patients for whom alternative treatments may be considered.
Journal Cover

December 2006
Volume 29 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

2013 Impact Factor: 2.773
Ranked #30/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Serra, M., Pasello, M., Manara, M., Scotlandi, K., Ferrari, S., Bertoni, F., Mercuri, M., Alvegard, T., Picci, P., Bacci, G., & Smeland, S. (2006). May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. International Journal of Oncology, 29(6), 1459-1468.
MLA
Serra, Pasello, Manara, Scotlandi, Ferrari, Bertoni, Mercuri, Alvegard, Picci, Bacci, and Sigbjørn Smeland. "May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol." International Journal of Oncology International Journal of Oncology 29.6 (2006): 1459-1468.
Chicago
Serra, Pasello, Manara, Scotlandi, Ferrari, Bertoni, Mercuri, Alvegard, Picci, Bacci, and Sigbjørn Smeland. "May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol." International Journal of Oncology International Journal of Oncology 29 no. 6 (2006): 1459-1468.